RNA interference screening for the discovery of oncology targets.
RNA interference (RNAi) mediated loss-of-function screens have the potential to delineate biological functions of genes and the proteins they encode. RNAi has proven to be a promising technology for identification and validation of new targets for the pharmacological treatment of many diseases including cancer. Here we review the use of high-throughput RNAi screens, examine the types of targets pursued for oncology indications, and discuss the integration of diverse datasets in both target discovery and drug discovery programs.
Quon
Kim
K
Amgen, Inc., Oncology Department, Seattle, WA 98119-3105, USA. kimq@amgen.com
Kassner
Paul D
PD
D000970:Antineoplastic Agents / Q000494:pharmacology; D016503:Drug Delivery Systems; D015195:Drug Design; D020868:Gene Silencing; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000503:physiopathology; D034622:RNA Interference
D000970:Antineoplastic Agents